BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9556047)

  • 1. Screening for Down syndrome at 14 weeks of pregnancy.
    Wald NJ; Watt HC; Haddow JE; Knight GJ
    Prenat Diagn; 1998 Mar; 18(3):291-3. PubMed ID: 9556047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in pregnancies with insulin-dependent diabetes: implications for screening for Down's syndrome.
    Wald NJ; Cuckle HS; Densem JW; Stone RB
    Br J Obstet Gynaecol; 1992 Jan; 99(1):51-3. PubMed ID: 1372176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-trimester maternal serum screening for Down's syndrome: free beta-human chorionic gonadotrophin (HCG) and alpha-fetoprotein, with or without unconjugated oestriol, compared with total HCG, alpha-fetoprotein and unconjugated oestriol.
    Extermann P; Bischof P; Marguerat P; Mermillod B
    Hum Reprod; 1998 Jan; 13(1):220-3. PubMed ID: 9512261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary evidence for associations between second-trimester human chorionic gonadotropin and unconjugated oestriol levels with pregnancy outcome in Down syndrome pregnancies.
    Benn PA
    Prenat Diagn; 1998 Apr; 18(4):319-24. PubMed ID: 9602476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome.
    Wald N; Cuckle H; Wu TS; George L
    Br J Obstet Gynaecol; 1991 Sep; 98(9):905-8. PubMed ID: 1716981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum markers for Down's syndrome in women who have had in vitro fertilisation: implications for antenatal screening.
    Wald NJ; White N; Morris JK; Huttly WJ; Canick JA
    Br J Obstet Gynaecol; 1999 Dec; 106(12):1304-6. PubMed ID: 10609726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of allowing for ethnic group in prenatal screening for Down's syndrome.
    Watt HC; Wald NJ; Smith D; Kennard A; Densem J
    Prenat Diagn; 1996 Aug; 16(8):691-8. PubMed ID: 8878277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining inhibin A with existing second-trimester markers in maternal serum screening for Down's syndrome.
    Cuckle HS; Holding S; Jones R; Groome NP; Wallace EM
    Prenat Diagn; 1996 Dec; 16(12):1095-100. PubMed ID: 8994244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Appropriate biochemical parameters in first-trimester screening for Down syndrome.
    Cuckle HS; van Lith JM
    Prenat Diagn; 1999 Jun; 19(6):505-12. PubMed ID: 10416963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [AFP, uE3, beta-hCG levels applied for prenatal diagnosis of Down's syndrome].
    Liao S; Wang Y; Ye G
    Zhonghua Fu Chan Ke Za Zhi; 1997 Nov; 32(11):655-8. PubMed ID: 9639764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-trimester diurnal variation of maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol: is it present and does it affect the prediction of a patient's risk for fetal Down syndrome?
    Rose NC; Canick JA; Knight GJ; Pulkkinen A; Tumber MB; Mennuti MT; Palomaki GE
    Prenat Diagn; 1994 Oct; 14(10):947-51. PubMed ID: 7534924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum markers for Down's syndrome in relation to number of previous births and maternal age.
    Wald NJ; Watt HC
    Prenat Diagn; 1996 Aug; 16(8):699-703. PubMed ID: 8878278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second trimester serum markers.
    Canick JA; MacRae AR
    Semin Perinatol; 2005 Aug; 29(4):203-8. PubMed ID: 16104669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are Down syndrome fetuses detected through maternal serum screening similar to those remaining undetected?
    Christiaens GC; Hagenaars AM; Akkerman C; De France HF
    Prenat Diagn; 1996 May; 16(5):437-42. PubMed ID: 8844002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First trimester biochemical screening for trisomy 21: the role of free beta hCG, alpha fetoprotein and pregnancy associated plasma protein A.
    Spencer K; Aitken DA; Crossley JA; McCaw G; Berry E; Anderson R; Connor JM; Macri JN
    Ann Clin Biochem; 1994 Sep; 31 ( Pt 5)():447-54. PubMed ID: 7530437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-trimester maternal serum inhibin-A screening for fetal Down syndrome in Asian women.
    Lam YH; Tang MH
    Prenat Diagn; 1999 May; 19(5):463-7. PubMed ID: 10360516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replacing Alpha-Fetoprotein With Alpha-Fetoprotein-L3 Increases the Sensitivity of Prenatal Screening for Trisomy 21.
    Huai L; Leng J; Ma S; Huang F; Shen J; Ding Y
    Am J Ther; 2016; 23(6):e1754-e1757. PubMed ID: 26938756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-trimester maternal serum biochemical indicators in Down syndrome.
    Brock DJ; Barron L; Holloway S; Liston WA; Hillier SG; Seppala M
    Prenat Diagn; 1990 Apr; 10(4):245-51. PubMed ID: 1694994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus.
    Huttly W; Rudnicka A; Wald NJ
    Prenat Diagn; 2004 Oct; 24(10):804-7. PubMed ID: 15503275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.